Axicabtagene: Indications in Pediatric Care & Adverse Effects

Introduction to Pediatric Axicabtagene Ciloleucel

MCQ Alert: The historical context and basic understanding of CAR T-cell therapy are frequently tested topics!

Axicabtagene ciloleucel (Yescarta) represents a groundbreaking advancement in pediatric oncology. While initially approved for adults in 2017, ongoing research and clinical trials have expanded its potential applications in pediatric populations. This therapy offers hope for children with refractory or relapsed B-cell malignancies who have exhausted conventional treatment options.

The journey of CAR T-cell therapy in pediatrics began with tisagenlecleucel (Kymriah), paving the way for axicabtagene ciloleucel's exploration in younger populations. The unique aspects of pediatric immune systems, including their enhanced plasticity and regenerative capacity, make this therapy particularly promising for children.



If Youare Bored, watch one of these ads

Powered by Blogger.
For mobile users: Use horizontal view or desktop mode for best experience.